Background Compared with vitamin K antagonists, direct-acting oral anticoagulants (DOACs)
have fixed dosing, limited drug interactions, and do not require therapeutic drug level …

Background/Objective Before approval of andexanet alfa, off‐label treatment with 4‐factor
prothrombin complex concentrate (4F‐PCC) was often utilized for the management of life‐…

Objective The purpose of this study was to estimate the time to recovery of command‐following
and associations between hypoxemia with time to recovery of command‐following. …

Background and Objectives In patients with severe coronavirus disease 2019 (COVID-19),
disorders of consciousness (DoC) have emerged as a serious complication. The prognosis …

There are currently no therapies proven to promote early recovery of consciousness in
patients with severe brain injuries in the intensive care unit (ICU). For patients whose families …

Pharmacologic interventions are commonly used to support rehabilitation efforts of patients
with disorders of consciousness (DoC). The 2018 practice guidelines recommend …

Axicabtagene ciloleucel and tisagenlecleucel are 2 chimeric antigen receptor (CAR) T-cell
immunotherapies targeting CD19 for the treatment of B-cell acute lymphoblastic leukemia …

Background Rituximab is a monoclonal antibody directed at CD20 positive B-lymphocytes
and a potential therapeutic option in the treatment of multiple sclerosis. The safety of recurrent …

Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …

Tranexamic acid (TXA) is an effective and commonly used hemostatic agent for perioperative
blood loss in various surgical specialties. It is being increasingly used in spinal deformity …